IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib
Mo, X-D1; Jiang, Q.1; Xu, L-P1; Liu, D-H1; Liu, K-Y1; Jiang, B.1; Jiang, H.1; Chen, H.1; Chen, Y-H1; Zhang, X-H1; Han, W.1; Wang, Y.1; Huang, X-J1
关键词Imatinib Hematopoietic Sct Health-related Quality Of Life Allogeneic Identical Sibling Donor
刊名BONE MARROW TRANSPLANTATION
2014-04-01
DOI10.1038/bmt.2013.232
49期:4页:576-580
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
资助者Key Program of National Natural Science Foundation of China ; Beijing Municipal Science &amp ; Technology Commission ; Key Program of National Natural Science Foundation of China ; Beijing Municipal Science &amp ; Technology Commission
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]STEM-CELL TRANSPLANTATION ; BONE-MARROW-TRANSPLANTATION ; CHRONIC MYELOGENOUS LEUKEMIA ; INTERFERON-ALPHA ; MEDICAL OUTCOMES ; WORKING PARTY ; FOLLOW-UP ; CML ; CHILDREN ; MESYLATE
英文摘要

To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell count >= 30x10(9)/L and plts count >= 450x10(9)/L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio =1.7, P= 0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.

语种英语
所属项目编号81230013 ; Z111107067311070
资助者Key Program of National Natural Science Foundation of China ; Beijing Municipal Science &amp ; Technology Commission ; Key Program of National Natural Science Foundation of China ; Beijing Municipal Science &amp ; Technology Commission
WOS记录号WOS:000334500900018
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51202
专题北京大学第二临床医学院
作者单位1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Mo, X-D,Jiang, Q.,Xu, L-P,et al. Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib[J]. BONE MARROW TRANSPLANTATION,2014,49(4):576-580.
APA Mo, X-D.,Jiang, Q..,Xu, L-P.,Liu, D-H.,Liu, K-Y.,...&Huang, X-J.(2014).Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib.BONE MARROW TRANSPLANTATION,49(4),576-580.
MLA Mo, X-D,et al."Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib".BONE MARROW TRANSPLANTATION 49.4(2014):576-580.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Mo, X-D]的文章
[Jiang, Q.]的文章
[Xu, L-P]的文章
百度学术
百度学术中相似的文章
[Mo, X-D]的文章
[Jiang, Q.]的文章
[Xu, L-P]的文章
必应学术
必应学术中相似的文章
[Mo, X-D]的文章
[Jiang, Q.]的文章
[Xu, L-P]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。